Capital Impact Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Capital Impact Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-59,577	Closed	-$950K	–	62
2024 Q1	$950K	Hold	59,577	–	–	1.23%	30
2023 Q4	$1M	Sell	59,577 -7,490	-11%	-$102K	1.32%	23
2023 Q3	$784K	Buy	67,067 +20,971	+45%	+$281K	1.31%	25
2023 Q2	$620K	Hold	46,096	–	–	0.68%	59
2023 Q1	$764K	Buy	46,096 +1,497	+3%	+$24.7K	0.94%	27
2022 Q4	$830K	Sell	44,599 -14,702	-25%	-$226K	0.81%	25
2022 Q3	$907K	Sell	59,301 -53,776	-48%	-$637K	0.9%	16
2022 Q2	$793K	Buy	113,077 +13,755	+14%	+$101K	0.73%	25
2022 Q1	$823K	Buy	+99,322	New	+$702K	0.6%	65
2020 Q4	–	Sell	-203,133	Closed	-$603K	–	106
2020 Q3	$603K	Hold	203,133	–	–	0.18%	107
2020 Q2	$938K	Hold	203,133	–	–	0.31%	104
2020 Q1	$782K	Buy	203,133 +23,265	+13%	+$95.5K	0.33%	100
2019 Q4	$675K	Hold	179,868	–	–	0.24%	114
2019 Q3	$948K	Buy	+179,868	New	+$958K	0.36%	114

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital Impact Advisors's CPRX Position: Q2 2024 in Review

Capital Impact Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q2 2024, closing a stake of 59,577 shares — an estimated $950K sold.

Capital Impact Advisors first reported a position in CPRX in Q3 2019 and held it in 14 quarters. The position peaked at $1M in Q4 2023. 271 funds tracked by Wall St. Rank hold CPRX as of Q2 2024.

Capital Impact Advisors reported no remaining Catalyst Pharmaceutical position as of Q2 2024 after selling out during the quarter.
Capital Impact Advisors sold 59,577 Catalyst Pharmaceutical shares in Q2 2024, an estimated $950K.
Capital Impact Advisors first reported a position in Catalyst Pharmaceutical in Q3 2019 and held it in 14 quarters.
Capital Impact Advisors's Catalyst Pharmaceutical position peaked at $1M in Q4 2023.
271 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2024.

Based on Capital Impact Advisors's 13F filing for Q2 2024, filed 16 Aug 2024.